Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

(2013) Hua-Xin Liao et al.   IMMUNITY

Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees

(2013) P. Liu et al.   JOURNAL OF VIROLOGY

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life

(2013) N L Yates et al.   Mucosal Immunology

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

(2013) Susan Zolla-Pazner et al.   PLoS One

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

(2013) G. D. Tomaras et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

More Woes for Struggling HIV Vaccine Field

(2013) J. Cohen   SCIENCE

The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120

(2012) Nicos Karasavvas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Targeting of Conserved Gag-Epitopes in Early HIV Infection Is Associated with Lower Plasma Viral Load and Slower CD4+ T Cell Depletion

(2012) Carina L. Perez et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Non-neutralizing antibodies in prevention of HIV infection

(2012) Harriet L. Robinson   EXPERT OPINION ON BIOLOGICAL THERAPY

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

(2012) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

(2012) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

(2012) Barton F Haynes et al.   NATURE BIOTECHNOLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-Specific Gag Responses in Early Infancy Correlate with Clinical Outcome and Inversely with Viral Load

(2011) Bongeka Nqoko et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Emerging Concepts on the Role of Innate Immunity in the Prevention and Control of HIV Infection

(2011) Margaret E. Ackerman et al.   Annual Review of Medicine

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

(2011) Lilin Lai et al.   JOURNAL OF INFECTIOUS DISEASES

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects☆☆☆

(2011) Michael C. Keefer et al.   VACCINE

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

(2011) Lilin Lai et al.   VACCINE

Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

(2010) Robert M Paris et al.   Expert Review of Vaccines

Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected HIV Vaccine Recipients

(2010) Cristine J. Cooper   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

(2008) G. D. Tomaras et al.   JOURNAL OF VIROLOGY

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

(2008) M Juliana McElrath et al.   LANCET

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA

(2007) Linda S. Wyatt et al.   VIROLOGY